US approves updated Pfizer, Moderna shots targeting Omicron / Photo: Joseph Prezioso - AFP/File
-
'No limits': Marathon world record holder Sawe chasing history
-
The eight stadiums for the 2027 Rugby World Cup
-
Countdown begins to biggest-ever Rugby World Cup
-
Thieves swipe drugs under nose of Fiji police, swap with flour
-
Bangladesh women lose ground after quota reform
-
South Korea demands North apologise for DMZ mine blasts
-
Vietnam admits 'differing opinions' on Hanoi development
-
In Nepal's flood zone, teachers mourn students who never returned
-
Stocks temper gains as oil pares heavy losses, US data in focus
-
US Supreme Court lifts limits on third-country deportations
-
New Zealand denies breaching climate commitments to EU
-
Antonelli eager to 're-establish order' as F1 returns to Malaysia
-
Albert becomes youngest US scorer in 4-2 win over Chile
-
Paw-fect candidate: Australia finds new koala rescue dog
-
Pirate island's plunging population shows Greece's demographic decline
-
One third of world population exposed to harmful air pollution: monitor
-
With elections ahead, Latvia's Russian-speakers reject Moscow's help
-
North Korea denies South's claim it was apparently behind DMZ mine blasts
-
Brazil football clubs face massive sponsorship blow from betting ban
-
West Bank's violent settlers part of a new generation fuelled by ideology
-
ChatGPT maker wants to be the App Store for AI as safety concerns grow
-
US-led coalition ends mission in Iraq
-
Women fight fires and sexism in Indonesian Borneo
-
Pope-backed White Sox join Braves with MLB playoff wins
-
Forsling's OT blast lifts Florida over Carolina in NHL opener
-
NBA close to picking new $12-13bn Vegas team owners: report
-
Hurricane Polo sweeps over Mexico's Pacific coast, heads inland
-
LA28 Olympics torch relay to visit all 50 states
-
Grynspan pulls ahead in race to lead UN: diplomat
-
Spain brush aside Croatia in Nations League, England down Czechs
-
Trump touts AI boss pledge to self-regulate
-
Trump hails 'morally binding' AI self-regulation pledge
-
Oil down, but stocks lower as bond yields rise
-
Yamal inspires Spain to Croatia romp on World Cup homecoming
-
England break down stubborn Czechs to claim first Nations League win
-
UN to hold fourth informal poll of secretary-general candidates
-
UN Security Council extends Haiti anti-gang force by 6 months
-
Who are the Emiratis behind crisis-hit Manchester City?
-
Manchester City guilty of Premier League charges: What comes next?
-
Singer Angelique Kidjo urges Africans to 'create together'
-
Man City chief Soriano slams Premier League 'conspiracy theory'
-
Alleged Rihanna mansion shooter mentally fit for trial, says judge
-
Hurricane Polo sweeps over Mexico's Pacific coast
-
Mystery over UK airbase scare as police find petrol not explosives
-
Man City must be relegated after guilty verdict says club's former chairman
-
OpenAI unveils low-cost AI model, a day after shelving Astra upgrade
-
German far-right aims to lead Saxony-Anhalt govt in December
-
Premier League confirms Man City guilty of serious financial breaches
-
Little damage as Hurricane Polo sweeps over Mexico's Pacific coast
-
Brazil's Lula turns to Bad Bunny tune to criticise Trump ahead of polls
US approves updated Pfizer, Moderna shots targeting Omicron
US health officials on Wednesday authorized updated Covid-19 vaccinations by Moderna and Pfizer-BioNTech that specifically target the latest strains of the Omicron variant, with the goal of jump-starting a new booster campaign.
The two updated booster shots aimed at providing "better protection against Covid-19 caused by the Omicron variant" are approved for people age 12 and above for the Pfizer shot and 18 and older for Moderna, the Food and Drug Administration (FDA) said in a statement.
This new generation of anti-Covid vaccines targets both the original strain of coronavirus and the BA.4 and BA.5 lineages, the subvariants of Omicron that are causing the most cases in the United States and which the FDA predicts will circulate in the coming months.
Earlier this summer the US health department announced it had purchased 105 million doses from Pfizer and 66 million from Moderna for use over the fall and winter.
The vaccines have yet to be recommended by the Centers for Disease Control and Prevention, the nation's health protection agency. But an independent panel of experts is scheduled to be convened by the CDC on Thursday to discuss the updates.
CDC director Rochelle Walensky will be in charge of giving the final green light.
The new versions of the vaccines could potentially be available in the United States as early as next week.
"Receiving a booster that specifically targets the Omicron BA.4/.5 variant, currently the most prevalent strain of SARS-CoV-2, is an important public health measure that people can take to help protect themselves, especially as we head into a season filled with indoor gatherings," Moderna chief executive Stephane Bancel said in a statement.
The vaccines currently in circulation target the initial strain of the virus that first appeared in Wuhan, China. But they have gradually proven to be less effective against the variants that have appeared over time, due to rapid evolution of the virus.
In contrast to the Alpha and Delta variants, which eventually waned, Omicron and its subvariants have come to dominate infections worldwide in 2022.
Pfizer and Moderna have also filed for approval of their updated vaccines with the European Medicines Agency.
R.Lee--AT
